Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective multicenter, assessor-blind, randomized, clinical trial

Coelingh Bennink, Herjan J.T.;Donnez, Jacques;Bassil, Salim;et.al.
(1998) Fertility and Sterility — Vol. 69, n° 1, p. 19-25 (1998)

Files

No attached file found for this publication.

Details

Authors
  • Coelingh Bennink, Herjan J.T.
    Author
  • Donnez, JacquesUCLouvain
    Author
  • Bassil, SalimUCLouvain
    Author
  • et. al.
Abstract
Objective: to compare the safety and efficacy of recombinant FSH (follitropin beta, Puregon, NV Organon, OSS The Netherlands) and urinary FSH (urofollitropin, Metrodin; Ares-Seronon, Geneva, Switzerland). Design: A prospective, multicenter, assessor-blind, randomized, clinical trial. Setting: 12 European infertility clinics. Patients: 172 women (recombinant FSH: n=105; urinary FSH: n=67) with clomiphene citrate-resistant normogonadotropic chronic anovulation (WHO group II). Interventions: eligible subjects were randomized (ratio of recombinant to urinary FSH, 3:2) and treated for a maximum of three cycles. A low-dose step-up regimen was used, with 75 IU of FSH given IM daily for a maximum of 14 days and, if needed, weekly increments of half an ampule given thereafter until the threshold dose for follicular development was achieved. Main outcome measures: cumulative ovulation rate after three cycles, total FSH dose, and treatment period needed to achieve anovulation. Results: the cumulative ovulation rates after three treatment cycles were 95% and 96% for the recombinant and urinary FSH groups, respectively. Overall, ovulation was seen in 155 of 223 treatment cycles (69.5%) in the recombinant FSH group, compared with 92 of 138 treatment cycles (66.7%) in the urinary FSH group.In the first cycle, a statistically significantly lower total dose (750 versus 1,035 UI)) and a shorter treatment period (10 vs 13 days) were needed in the recombinant FSH group to reach ovulation. Only one case of ovarian hyperstimulation syndrome led to hospitalization. Two sets of twin (1 in each treatment group) and 1 set of triplets (in the recombinant FSH group) were born. Conclusions: recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in inducing follicular development
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Coelingh Bennink, H. J. T., Donnez, J., Bassil, S., & et al. (1998). Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective multicenter, assessor-blind, randomized, clinical trial. Fertility and Sterility, 69(1), 19-25. https://hdl.handle.net/2078.5/74853 (Original work published 1998)